- The trend backdrop is active with a 12-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
INNOVACAP
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Innova Captab Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
944.5 INR
-3.1%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 17.9% above the Trend Line and sits at 78.1% of its 52-week range. The latest completed week returned -3.1%, after a -4.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal.
Setup score
61
out of 100
Latest Close
944.5 INR
7 Aug 2026
1W Return
-3.1%
latest completed week
4W Return
-4.5%
short-term follow-through
12W Return
10.0%
quarterly tape
Trend Breadth
34.6%
18 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.1%
Latest completed week; four-week move -4.5%.
Indicator stack
61/70
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
20 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 17.9% above the Trend Line and sits at 78.1% of its 52-week range. The latest completed week returned -3.1%, after a -4.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9312-week average 0.69
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.93Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -4.5% over four weeks, 10.0% over 12 weeks, and 3.3% over one year. The current trend has remained active for 12 consecutive weeks.
Performance by holding period
Active trend streak12 weeks
Active weeks in one year18
Trend breadth34.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.26Latest activity-pressure read.
Pressure change-32.5%Four-week change in activity pressure.
Leadership18.70Latest relative-leadership reading.
RS change-31.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength38/100Blend of value, momentum, and quality. Underlying universe rank 63; rank 1 is best.
Value24/100Relative valuation strength. Underlying universe rank 77; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum69/100Medium-term price momentum. Underlying universe rank 32; rank 1 is best.
Growth77/100Revenue and earnings growth. Underlying universe rank 24; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework34/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 38.4x Price divided by trailing earnings.
- Price / sales
- 3.3x Market value relative to trailing revenue.
- EV / EBITDA
- 23.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 0.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 35.4% Gross profit retained from each unit of revenue.
- Operating margin
- 11.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 3.0% Free cash flow generated from revenue.
- Return on invested capital
- 10.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 29.9% Latest one-year revenue growth.
- EPS growth
- 9.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.2% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 20 relevant articles.
4 positive · 16 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-8.7%Distance below the 52-week high.
13-week volatility3.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+16.4%Week of 8 May.
Worst week-4.8%Week of 20 Mar.
Latest week-3.1%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks0
Modest losses11
Sharp losses2
Recent vol3.0%13-week weekly-return volatility.
Base vol3.9%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew3.1% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank78 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank64 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape64/100
Trend, activity pressure, participation, and risk combine to a 64/100 tape read.
Indicator analysis90/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.93; No reversal markers Factors48/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 39; Small Cap Core rank 79 SVQF34/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1033.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 20 relevant articles.
Innova Captab files BRSR for FY26, exports rise to 23% Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 944.5 INR | -3.1% | 801.2 INR | 759.2 INR | 1.26 | 18.70 | 110.5K | On |
| 31 Jul 2026 | 975.0 INR | 2.6% | 793.1 INR | 757.8 INR | 1.64 | 23.54 | 122.6K | On |
| 24 Jul 2026 | 950.5 INR | -1.3% | 784.7 INR | 756.2 INR | 1.74 | 23.85 | 178.2K | On |
| 17 Jul 2026 | 962.7 INR | -2.7% | 776.6 INR | 754.8 INR | 1.88 | 22.79 | 209.2K | On |
| 10 Jul 2026 | 989.3 INR | 3.3% | 767.4 INR | 753.2 INR | 1.86 | 27.12 | 414.8K | On |
| 3 Jul 2026 | 957.8 INR | 1.8% | 758.4 INR | 751.4 INR | 1.82 | 23.20 | 38.9K | On |
| 26 Jun 2026 | 941.3 INR | -0.9% | 750.0 INR | 749.8 INR | 1.77 | 22.59 | 0 | On |
| 19 Jun 2026 | 949.5 INR | 0.8% | 742.5 INR | 748.4 INR | 1.76 | 24.31 | 28.4K | On |
| 12 Jun 2026 | 942.5 INR | 8.6% | 736.1 INR | 746.8 INR | 1.76 | 25.86 | 127.6K | On |
| 5 Jun 2026 | 867.5 INR | 2.0% | 729.6 INR | 745.3 INR | 1.77 | 17.36 | 24.4K | On |
| 29 May 2026 | 850.4 INR | 0.2% | 726.2 INR | 744.3 INR | 1.90 | 14.28 | 192.4K | On |
| 22 May 2026 | 848.3 INR | -1.2% | 725.5 INR | 743.5 INR | 1.95 | 13.22 | 224.2K | On |
| 15 May 2026 | 858.3 INR | -2.0% | 724.0 INR | 742.6 INR | 1.85 | 14.93 | 288.9K | Off |
| 8 May 2026 | 875.8 INR | 16.4% | 722.2 INR | 741.7 INR | 1.73 | 14.64 | 1.4M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.